CN1101281A - Preparation of ke'ao Jiugan Lin - Google Patents
Preparation of ke'ao Jiugan Lin Download PDFInfo
- Publication number
- CN1101281A CN1101281A CN 94111678 CN94111678A CN1101281A CN 1101281 A CN1101281 A CN 1101281A CN 94111678 CN94111678 CN 94111678 CN 94111678 A CN94111678 A CN 94111678A CN 1101281 A CN1101281 A CN 1101281A
- Authority
- CN
- China
- Prior art keywords
- radix
- hepatitis
- medicine
- excipient
- dextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A Chinese medicine for curing hepatitis B consists of flos chrysanthemi indici, herba seu radix cirsii japonici, radix bupleuri, radix salviae miltiorrhizae, polyporus umbellatus, etc. 16 kinds of Chinese medicines which are washed, sliced, dried, ground, secreened, then mixed in proportion,a dded to proper quantity of excipient and humectant, at last prilled, dried and sealed in bottle. It virtues no toxicity and side-effect for curing hepatitis B and after three month application the effective rate reaches 99.5%. The turn-negative rate of hepatitis B surface antigen and e antigen reach 88.5% and 100% respectively, the generative rate of surface antibody is 71.14%. During nine-year observation nobody relapsed.
Description
The invention belongs to a kind of production method for the treatment of the hepatitis B medicine.
Hepatitis B is a kind of infectious disease of serious harm human health, its infection rate height is to invade liver by hepatitis B virus, causes the stagnation of QI, blood stasis, wet sun, with the passing of time the healthy energy of liver is lost, deficiency in origin and excess in superficiality causes hepatic fibrosis, liver cirrhosis so that hepatocarcinoma at last and comes to an end.At present, there is the hepatitis B patient more than 2,100,000,000 in the whole world, the domestic hepatitis B patient who has more than 3.5 hundred million, therefore, the researcher of countries in the world is all in the development of paying attention to the second drug for liver disease, as having in the normal on the market hepatitis B medicine that uses now: the safe electuary of the sesame liver that rues, the clever GANFUKANG difficult to understand of going out, liver must be answered, medicine for treatment of hepatic disease, Fuganning, the detoxication of hepatitis B soft gelatin capsule, agent in hepatitis B by strengthening body resistance soft gelatin capsule and Chaoyang, Beijing ball and the CN 1076626A hepatopathy, CN 1056423A Qingganbao oral liquid compounding method, the grand manufacture method of the sharp liver of CN 1032295A, the medicine of these treatment hepatitis B, its weak point is the long weak effect of treatment cycle, taking for a long time of having also has the effect of paying, and expense is also very high.
The purpose of this invention is to provide a kind of treatment hepatitis B and do not have any pair of effect, and hepatitis B virus there are very strong inhibition and deactivation, can excite the hepatitis b immune production of antibodies, surface antibody generation rate height, it is short to be difficult for recurrence and treatment time after curing, the production method of the hepatitis B new drug that medical expense is low.
The present invention adopts the scheme of heat-clearing and toxic substances removing, depressed liver-energy dispersing and QI regulating, promoting flow of QI and blood, function of gallbladder promoting dehumidifying, QI invigorating tonify deficiency that hepatitis B is treated according to the morbidity base reason of hepatitis B.Process of the present invention is: Rhizoma Osmundae, Radix Cirsii Japonici, Radix Scutellariae, Radix Bupleuri, Radix Salviae Miltiorrhizae, Polyporus, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Radix Ginseng gross weight content are that 40-60%, the Radix Astragali, Radix Curcumae, white bandit, Cacumen Securinegae Suffruticosae, Radix Codonopsis gross weight content are that 20-40%, Flos Chrysanthemi Indici, Radix Glycyrrhizae gross weight content are 10-30%, above-mentioned medicine is cleaned roguing respectively, the section oven dry is pulverized, the granularity of sieving is the 150-200 order, the sterilization that mixes according to the above ratio, carries out disinfection adds excipient then and makes electuary.(excipient is made up of Icing Sugar, dextrin, starch, with the medicated powder weight ratio be medicated powder 8 Icing Sugar 3 dextrin 2, starch 1 carries out mix homogeneously), add 75% ethanol again and make wetting agent, make at last that granule is dried under 65 ℃ of conditions, package encapsulation.
Hepatitis B new drug three big advantages with our legal system: one, selected medicine is nontoxic, eliminating evil and not high suddenly, set upright and not dull, effect is gentle, can obey for a long time.Two, select medicine with strong points, both can be eliminating evil with conditioning functions, can set upright again improve immunologic function, effect is better.Though three, various medicines targetedly but complement each other, bring out the best in each other.
Embodiment:
Flos Chrysanthemi Indici, Rhizoma Osmundae, Radix Cirsii Japonici, Radix Scutellariae, Radix Bupleuri, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Radix Paeoniae Alba total weight are 53 grams, Polyporus, the Radix Astragali, Radix Ginseng, Radix Curcumae, the bandit amounts to weight 25 grams in vain, Cacumen Securinegae Suffruticosae, Radix Codonopsis add up to 15 grams, again add Radix Glycyrrhizae 7 gram, above-mentioned medicine is cleaned roguing respectively, section oven dry pulverizes, sieves, then according to the above ratio the batch mixes disinfection, at last medicated powder and excipient are mixed in proportion, add again adequate amount of ethanol as wetting agent make granular, under 65 ℃ condition, dry granulating, last sealed packaging, the ke ao Jiugan Lin medicine of treatment hepatitis B.
People surplus having 1000 with the hepatitis B patient of this ke ao Jiugan Lin treatment, treat after three months, effective percentage reaches 99.5%, surface antigen (HBsAg) titre descends significantly, rate of descent is 100%, and surface antigen (HBsAg) negative conversion rate is up to 88.5%, and e antigen (HBsAg) negative conversion rate reaches 100%, surface antibody is (anti--HBs) generation rate 75.14%HBV-DNA negative conversion rate 100%, through 9 years long-term effect tracing observations, stable curative effect, none routine patient's recurrence.Be to treat the best new drug of hepatitis B at present both at home and abroad.
Claims (3)
1, a kind of manufacture method for the treatment of the hepatitis B medicine, it is characterized in that: weight is that Flos Chrysanthemi Indici, the Radix Glycyrrhizae of the Radix Astragali, Radix Curcumae, white bandit, Cacumen Securinegae Suffruticosae, Radix Codonopsis and the 10-30% of Rhizoma Osmundae, Radix Cirsii Japonici, Radix Scutellariae, Radix Bupleuri, Radix Salviae Miltiorrhizae, Polyporus, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Radix Ginseng and the 20-40% of 40-60% formed, above-mentioned medicine is cleaned roguing respectively, section, oven dry crushing screening, then according to the above ratio the batch mixes disinfection, add excipient and wetting agent pelletize, oven dry bottling sealing at last.
2, excipient according to claim 1 is characterized in that: be made up of Icing Sugar, dextrin, starch, its addition is that medicated powder and Icing Sugar, dextrin and starch proportion are 8: 3: 2: 1
3, wetting agent according to claim 1 is characterized in that: adding concentration of ethanol is 75%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94111678 CN1101281A (en) | 1994-03-15 | 1994-03-15 | Preparation of ke'ao Jiugan Lin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94111678 CN1101281A (en) | 1994-03-15 | 1994-03-15 | Preparation of ke'ao Jiugan Lin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1101281A true CN1101281A (en) | 1995-04-12 |
Family
ID=5035519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94111678 Pending CN1101281A (en) | 1994-03-15 | 1994-03-15 | Preparation of ke'ao Jiugan Lin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1101281A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0837688A4 (en) * | 1995-07-10 | 1999-03-03 | Cathay Herbal Lab Pty Ltd | Herbal compositions for hepatic disorders |
| CN1085548C (en) * | 1999-03-31 | 2002-05-29 | 广州医学院第二附属医院 | Traditional Chinese medicinal prepns. for treating hepatitis B virus, and method for preparing same |
| CN103655882A (en) * | 2013-12-18 | 2014-03-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition for treating hepatitis C and preparation method of composition |
-
1994
- 1994-03-15 CN CN 94111678 patent/CN1101281A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0837688A4 (en) * | 1995-07-10 | 1999-03-03 | Cathay Herbal Lab Pty Ltd | Herbal compositions for hepatic disorders |
| US6426098B1 (en) * | 1995-07-10 | 2002-07-30 | Cathay Herbal Laboratories | Herbal compositions for hepatic disorders |
| CN1085548C (en) * | 1999-03-31 | 2002-05-29 | 广州医学院第二附属医院 | Traditional Chinese medicinal prepns. for treating hepatitis B virus, and method for preparing same |
| CN103655882A (en) * | 2013-12-18 | 2014-03-26 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition for treating hepatitis C and preparation method of composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1044974C (en) | Anti- hepatitis B preparation | |
| CN1194843A (en) | Method for producing green health medicine | |
| CN1951481A (en) | Medicament for treating cerebral thrombosis | |
| CN1127128A (en) | Traditional Chinese medicine for cholelithiasis and preparing method | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1062157C (en) | Hepatitis B curing toxin-dissipating pill | |
| CN1336219A (en) | Gynopathy treating traditional Chinese medicine | |
| CN112891399A (en) | Traditional Chinese medicine composition and application and preparation method thereof | |
| CN1270765C (en) | Medicinal wine or liquid for treating cold | |
| CN1101281A (en) | Preparation of ke'ao Jiugan Lin | |
| CN111759951A (en) | Preparation method and application of functional dendrobe coffee for dredging human gonad channel | |
| CN1232288C (en) | Chinese medicine aqueous pill preparation for treating hepatitis B and its preparation process | |
| CN1150926C (en) | Medicine for treating hepatism | |
| CN1160560A (en) | Chinese patent drug for curing leukopenia and its preparation process | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN1058911A (en) | The compound method of capsule for curing tumour | |
| CN1094628A (en) | Antidiarrheal Chinese medicine | |
| CN1062176C (en) | Oral liquid for curing cancer | |
| CN1054977C (en) | Terrapin shell deer antler pellet and its prepn. process | |
| CN1086141C (en) | Medicine for treating early-stage hepatocirrhosis and its preparation | |
| CN1195541C (en) | Medicine combination for treating chronic hepatitis B | |
| CN1114885A (en) | External-use medicine powder for health care, nourishing kidney and clearing brain | |
| CN1195531C (en) | Chinese medicinal herbs prescription for treating hepatitis B | |
| CN1150929C (en) | Malian granule for clearing away liver fire | |
| CN1321474A (en) | Yigan Jiedu tea for curing hepatitis B and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |